Emerging therapeutic strategies for myelodysplastic syndrome.
Increasing understanding of the pathophysiology of myelodysplastic syndromes (MDS) and a greater appreciation of the large impact that marrow failure has on the symptomatology and outcome of MDS have led to new treatment approaches. We describe recent developments of methods to manage marrow failure, suppress the MDS clone, and widen the applicability of curative treatment with allogeneic stem cell transplants.
Barrett
John
J
Stem Cell Allotransplantation Section, Hematology Branch, NHLBI, NIH, Building 10, Room 7C103, 9000 Rockville Pike, Bethesda, MD 20892, USA. barrettj@nih.gov
Battiwalla
Minoo
M
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002999:Clone Cells / Q000187:drug effects / Q000473:pathology; D019468:Disease Management; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents